AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12027911 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 1265
Study 12027911 — intervention group
Group type: COMPARATOR
Intervention: Valproate (VPA)
Number of subjects: 1265
Study 9799053 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg) pre-treatment for 4 days and co-administration with cerivastatin (0.3 mg)
Number of subjects: 12
Study 9799053 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin (0.3 mg) alone
Number of subjects: 12
Study 7643540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 73
Study 2677610 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% omega-3 diet
Number of subjects: 27
Study 2677610 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% omega-3 diet
Number of subjects: 27
Study 2677610 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 diet (various sequences)
Number of subjects: 27
Study 2677610 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid diet in healthy controls
Number of subjects: 27
Study 352184 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg intravenously
Number of subjects: 20
Study 352184 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenous injection
Number of subjects: 20
Study 30291760 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with at least one other adult in the household
Number of subjects: 137
Study 30291760 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of adults in the house
Number of subjects: 137
Study 30291760 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer family hassles
Number of subjects: 137
Study 28506937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 78
Study 28506937 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 78
Study 25447301 — intervention group
Group type: EXPERIMENTAL
Intervention: 1M sucrose solution (SU)
Number of subjects: 49
Study 25447301 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva (AS)
Number of subjects: 49
Study 23895849 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm clipping and partial blood clot removal in the subarachnoid space
Number of subjects: 0
Study 23895849 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm clipping and blood clot removal
Number of subjects: 0
Study 21463074 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) with Standard Care (SC)
Number of subjects: 393
Study 21463074 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) alone
Number of subjects: 393
Study 19555360 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month oral function promotion programme including facial muscle and tongue exercises and salivary gland massages
Number of subjects: 141
Study 19555360 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 141
Study 16540101 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct gaze
Number of subjects: 0
Study 16540101 — intervention group
Group type: EXPERIMENTAL
Intervention: Averted gaze
Number of subjects: 0
Study 16540101 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct gaze and averted gaze
Number of subjects: 0
Study 15692318 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement (400 IU vitamin E, 1 g vitamin C, 90 µg selenium per day)
Number of subjects: 18
Study 15692318 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 18
Study 11928800 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy‐based regimens
Number of subjects: 67
Study 11928800 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 67
Study 11928800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine therapy
Number of subjects: 67
Study 9819503 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia (Group II)
Number of subjects: 20
Study 9819503 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cold crystalloid cardioplegia (Group I)
Number of subjects: 20
Study 9819503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 7522487 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) as part of induction treatment for good-prognosis patients
Number of subjects: 78
Study 7522487 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan plus interferon (MP+IFN)
Number of subjects: 78
Study 7522487 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan plus prednisone (MP)
Number of subjects: 78
Study 7522487 — intervention group
Group type: COMPARATOR
Intervention: Maintenance treatment with interferon (IFN)
Number of subjects: 78
Study 2572145 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem (150 mg/day, 50 mg t.i.d. for 3 weeks)
Number of subjects: 59
Study 2572145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 4563483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 60 mg/day
Number of subjects: 15
Study 4563483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 150 mg/day
Number of subjects: 15
Study 4563483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29474208 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls Active intervention group
Number of subjects: 1734
Study 29474208 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1734
Study 29474208 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1734
Study 28340073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB) based empirical left atrial appendage (LAA) isolation in addition to pulmonary vein isolation (PVI)
Number of subjects: 100
Study 28340073 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI) only
Number of subjects: 100
Study 25747273 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with activated CIK cells (injection of 6.4 × 10(9) autologous CIK cells, 16 times during 60 weeks)
Number of subjects: 230
Study 25747273 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 230
Study 25747273 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with activated CIK cells
Number of subjects: 230
Study 23026547 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 188
Study 21114826 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist depression disorder team (psychiatrist and psychotherapist jointly assessing and providing algorithm based drug and psychological treatment)
Number of subjects: 174
Study 21114826 — intervention group
Group type: COMPARATOR
Intervention: Usual secondary care treatment
Number of subjects: 174
Study 21114826 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist depression disorder team
Number of subjects: 174
Study 18067986 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific ONS (Diasip)
Number of subjects: 40
Study 18067986 — intervention group
Group type: COMPARATOR
Intervention: Standard ONS
Number of subjects: 40
Study 17093281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer control strategies
Number of subjects: 0
Study 17093281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer follow-up care guidelines
Number of subjects: 0
Study 17093281 — intervention group
Group type: EXPERIMENTAL
Intervention: Research on cancer survivorship
Number of subjects: 0
Study 12888141 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of myocardial performance (IMP)
Number of subjects: 50
Study 12888141 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolumic contraction time (IVCT)
Number of subjects: 50
Study 12888141 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolumic relaxation time (IVRT)
Number of subjects: 50
Study 12888141 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler intervals
Number of subjects: 50
Study 10643405 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm grip (P)
Number of subjects: 9
Study 10643405 — intervention group
Group type: COMPARATOR
Intervention: Finger grip (F)
Number of subjects: 9
Study 10643405 — intervention group
Group type: COMPARATOR
Intervention: Surgical haemostat clamp (H)
Number of subjects: 9
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: Blacks (n = 45)
Number of subjects: 938
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: Whites (n = 492)
Number of subjects: 938
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: Hispanics (n = 278)
Number of subjects: 938
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: Asians (n = 58)
Number of subjects: 938
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: Asians with hepatitis B excluded (n = 43)
Number of subjects: 938
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B surface antigen positive Asians (n = 15)
Number of subjects: 938
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: PRA < 10% (n = 339)
Number of subjects: 938
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: Positive antidonor flow cytometry crossmatch (> 30 mean channel shifts, n = 76)
Number of subjects: 938
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: 0 DR mismatches
Number of subjects: 938
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: 1 DR mismatches
Number of subjects: 938
Study 8896726 — intervention group
Group type: COMPARATOR
Intervention: 2 DR mismatches
Number of subjects: 938
Study 1829879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 120
Study 1829879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime combined with teicoplanin
Number of subjects: 120
Study 7051741 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TNS) over low-back and suprapubic region
Number of subjects: 24
Study 7051741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TNS, only conventional methods)
Number of subjects: 24
Study 7051741 — intervention group
Group type: EXPERIMENTAL
Intervention: TNS and conventional methods
Number of subjects: 24
Study 7051741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TNS)
Number of subjects: 24
Study 7051741 — intervention group
Group type: EXPERIMENTAL
Intervention: TNS and control group
Number of subjects: 24
Study 7051741 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates from both groups
Number of subjects: 24
Study 30998770 — intervention group
Group type: EXPERIMENTAL
Intervention: SegNet method
Number of subjects: 0
Study 30998770 — intervention group
Group type: COMPARATOR
Intervention: FCN method
Number of subjects: 0
Study 30998770 — intervention group
Group type: COMPARATOR
Intervention: U-Net method
Number of subjects: 0
Study 29907887 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 (300 mg) after a single dose at fed state with a standard meal
Number of subjects: 2
Study 29907887 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 (300 mg) after a single dose at fed state with a high-fat meal
Number of subjects: 2
Study 29907887 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 (100 mg) after multiple dosing for 7 days in fed state with a standard meal
Number of subjects: 2
Study 26098401 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 26
Study 26098401 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Therapy (RT)
Number of subjects: 26
Study 26098401 — intervention group
Group type: COMPARATOR
Intervention: Historical group (retrospective data)
Number of subjects: 26
Study 24435507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10, 5, 5 mg/kg every 24 h)
Number of subjects: 83
Study 24435507 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin (0.20‐0.25 mg/kg every 24 h)
Number of subjects: 83
Study 24435507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (early postnatal age <8 days)
Number of subjects: 83
Study 24435507 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin (early postnatal age <8 days)
Number of subjects: 83
Study 24435507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (neonates >28 weeks)
Number of subjects: 83
Study 24435507 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin (neonates >28 weeks)
Number of subjects: 83
Study 24435507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (birth weight >1,000 g)
Number of subjects: 83
Study 24435507 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin (birth weight >1,000 g)
Number of subjects: 83
Study 22000982 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-AVCP group (<64 ms, n = 3)
Number of subjects: 7
Study 22000982 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-AVCP group (>64 ms, n = 4)
Number of subjects: 7
Study 22000982 — intervention group
Group type: COMPARATOR
Intervention: Short-AVCP group
Number of subjects: 7
Study 19188808 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise session (25-min cycling)
Number of subjects: 13
Study 19188808 — intervention group
Group type: COMPARATOR
Intervention: Control (25-min seated at rest)
Number of subjects: 13
Study 17967610 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 200
Study 17967610 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 200
Study 16215965 — intervention group
Group type: EXPERIMENTAL
Intervention: REX-DIR gated
Number of subjects: 12
Study 16215965 — intervention group
Group type: COMPARATOR
Intervention: REX-DIR non-gated
Number of subjects: 12
Study 16215965 — intervention group
Group type: EXPERIMENTAL
Intervention: IOSB gated
Number of subjects: 12
Study 16215965 — intervention group
Group type: COMPARATOR
Intervention: IOSB non-gated
Number of subjects: 12
Study 11865834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 1600 mg daily
Number of subjects: 18
Study 11865834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10588294 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural Mean Model (SMM)
Number of subjects: 0
Study 10588294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary Least-Squares (OLS) estimator
Number of subjects: 0
Study 10588294 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline covariates
Number of subjects: 0
Study 10588294 — intervention group
Group type: EXPERIMENTAL
Intervention: Run-in period
Number of subjects: 0
Study 7762854 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O (50%) and 0.5 MAC sevoflurane (1%)
Number of subjects: 40
Study 7762854 — intervention group
Group type: COMPARATOR
Intervention: 1.0 MAC sevoflurane
Number of subjects: 40
Study 7762854 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O (60%) and 0.5 MAC isoflurane (0.6%)
Number of subjects: 40
Study 7762854 — intervention group
Group type: COMPARATOR
Intervention: 1.0 MAC isoflurane
Number of subjects: 40
Study 2324941 — intervention group
Group type: EXPERIMENTAL
Intervention: Distracting-active response condition
Number of subjects: 69
Study 2324941 — intervention group
Group type: EXPERIMENTAL
Intervention: Distracting-passive response condition
Number of subjects: 69
Study 2324941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminative-active response condition
Number of subjects: 69
Study 2324941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminative-passive response condition
Number of subjects: 69
Study 7439477 — intervention group
Group type: EXPERIMENTAL
Intervention: SADBE (squaric acid dibutylester) applied weekly to one side of the head
Number of subjects: 53
Study 7439477 — intervention group
Group type: COMPARATOR
Intervention: Control side (no treatment)
Number of subjects: 53
Study 7439477 — intervention group
Group type: EXPERIMENTAL
Intervention: SADBE (squaric acid dibutylester)
Number of subjects: 53
Study 30165506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster robustness score with increasing amounts of noise (zero mean and increasing variance)
Number of subjects: 0
Study 29960684 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiotherapy (RT) at 60 Gy
Number of subjects: 56
Study 27388492 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery training
Number of subjects: 36
Study 27388492 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual-motor training (PMT)
Number of subjects: 36
Study 27388492 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 36
Study 25316463 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdentures
Number of subjects: 50
Study 22532781 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirena((R)) for 5 years (in patients not submitted to endometrial resection)
Number of subjects: 89
Study 22532781 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirena((R)) after endometrial resection
Number of subjects: 89
Study 22532781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormonal treatment)
Number of subjects: 89
Study 19965532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (USG) insertion
Number of subjects: 110
Study 19965532 — intervention group
Group type: COMPARATOR
Intervention: Anatomical landmark-guided technique (ALT)
Number of subjects: 110
Study 17937690 — intervention group
Group type: EXPERIMENTAL
Intervention: B221 (2 g every 5 hours for 3 days)
Number of subjects: 240
Study 15045043 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐BDP 800 microg/day
Number of subjects: 141
Study 15045043 — intervention group
Group type: COMPARATOR
Intervention: CFC‐BDP 1500 microg/day
Number of subjects: 141
Study 11665810 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull Energy Drink
Number of subjects: 36
Study 11665810 — intervention group
Group type: COMPARATOR
Intervention: Control drinks
Number of subjects: 36
Study 9840605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ARTS (120 mg)
Number of subjects: 12
Study 9840605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ARTS (100 mg)
Number of subjects: 12
Study 8130815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectic subjects (BMI: 14.5 ± 0.8 kg/m²)
Number of subjects: 32
Study 8130815 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (BMI: 20.3 ± 0.5 kg/m²)
Number of subjects: 32
Study 8130815 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI: 33.0 ± 0.9 kg/m²)
Number of subjects: 32
Study 8130815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectic subjects
Number of subjects: 32
Study 8130815 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 32
Study 8130815 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 32
Study 2781110 — intervention group
Group type: EXPERIMENTAL
Intervention: diatrizoate (group I)
Number of subjects: 60
Study 2781110 — intervention group
Group type: EXPERIMENTAL
Intervention: ioxaglate (group IIA)
Number of subjects: 60
Study 2781110 — intervention group
Group type: COMPARATOR
Intervention: ioxaglate (group IIB)
Number of subjects: 60
Study 2781110 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (group III)
Number of subjects: 60
Study 945686 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 20
Study 945686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 20
Study 945686 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository control group
Number of subjects: 20
Study 30586727 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC-stroke score
Number of subjects: 8705
Study 30586727 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC-bleeding score
Number of subjects: 8705
Study 30586727 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban treatment
Number of subjects: 8705
Study 30586727 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated hsTnT, NT-proBNP, and GDF-15
Number of subjects: 8705
Study 30586727 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated hsTnT and GDF-15
Number of subjects: 8705
Study 27522513 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100mg once before surgery, then 25mg on postoperative days 0, 1, and 2)
Number of subjects: 233
Study 27522513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 27522513 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 233
Study 26080912 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (270 mgI/ml of contrast medium, 80 kVp tube voltage scanning and 50% ASiR)
Number of subjects: 58
Study 26080912 — intervention group
Group type: COMPARATOR
Intervention: Group B (350 mgI/ml of contrast medium, 120 kVp routine tube voltage)
Number of subjects: 58
Study 26080912 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 58
Study 26080912 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 58
Study 23271695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bioactive food ingredients (epigallocatechin gallate, capsaicins, piperine, L-carnitine)
Number of subjects: 86
Study 23271695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 21733979 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive spirometry training
Number of subjects: 397
Study 21733979 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 397
Study 19840309 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily pimecrolimus cream 1%
Number of subjects: 268
Study 19840309 — intervention group
Group type: COMPARATOR
Intervention: Once-daily pimecrolimus cream 1%
Number of subjects: 268
Study 16495416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic single operator (D1)
Number of subjects: 44
Study 16495416 — intervention group
Group type: COMPARATOR
Intervention: Dynamic two operator (D2)
Number of subjects: 44
Study 15286858 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplement (20 g of Creatine monohydrate for 14 days)
Number of subjects: 14
Study 15286858 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrine)
Number of subjects: 14
Study 16978630 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected men
Number of subjects: 263